WO2022074313A1 - Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique - Google Patents

Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique Download PDF

Info

Publication number
WO2022074313A1
WO2022074313A1 PCT/FR2021/051694 FR2021051694W WO2022074313A1 WO 2022074313 A1 WO2022074313 A1 WO 2022074313A1 FR 2021051694 W FR2021051694 W FR 2021051694W WO 2022074313 A1 WO2022074313 A1 WO 2022074313A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptoid
peptoids
independently
trip8b
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2021/051694
Other languages
English (en)
French (fr)
Inventor
Jérôme BUSSEROLLES
Emmanuel Bourinet
Claude TAILLEFUMIER
Olivier Roy
Lionel NAUTON
Youssef AISSOUNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, University of Montpellier, Université Clermont Auvergne, Sigma Clermont filed Critical Centre National de la Recherche Scientifique
Priority to CA3194875A priority Critical patent/CA3194875A1/fr
Priority to JP2023521558A priority patent/JP7853288B2/ja
Priority to CN202180068718.2A priority patent/CN116744957A/zh
Priority to ES21798748T priority patent/ES3005857T3/es
Priority to EP21798748.6A priority patent/EP4225295B1/fr
Priority to US18/248,240 priority patent/US20230374067A1/en
Publication of WO2022074313A1 publication Critical patent/WO2022074313A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to new peptidomimetic molecules (or peptoids, also called peptide-peptoid hybrids or peptomers) for the prevention and/or treatment of chronic pain, in particular that resulting from peripheral neuropathies (e.g. induced by chemotherapy).
  • peptoids also called peptide-peptoid hybrids or peptomers
  • references in square brackets ([ ]) refer to the list of references at the end of the text.
  • Chronic pain affects 1.5 billion people worldwide for whom the therapeutic response is clearly insufficient (Finnerup NB et al., 2015) [1]. Recent epidemiological studies have estimated that chronic pain affects around 20% of adults and 50% of older people (von Hehn et al., 2012) [2]. Globally, 60% of people with pain are less able to work and 20% say they lost their job because of the pain. At the same time, 20 billion units of analgesic drugs were sold in 2010, against 14 billion in 2005 (+9.3%). In 2017, the global pain market reached $61.05 billion and is expected to gross $77.13 billion by 2023, registering a compound annual growth rate of 4% from 2017 to 2023.
  • Neuropathic pain affects about 7% of the general population and 25% of patients with chronic pain. They are of two types: peripheral neuropathic pain (depending on its origin, it can concern the territories of a plexus, a root, a trunk or be more diffuse in the context of polyneuropathies) and central neuropathic pain ( lesions affecting sensory pathways or pain control).
  • Peripheral neuropathies induced by chemotherapy frequent adverse effects of many anti-cancer agents, are characterized by significant chronic pain that has a lasting effect on the quality of life of patients and leads to dosage adjustments with the risk of reduced clinical efficacy.
  • the analgesic pharmacopoeia which is getting poorer (withdrawal of Di-antalvic in 2011), is characterized by old and often poorly tolerated treatments.
  • HCN channels are widely distributed in pain pathways and play an important role in the development and maintenance of neuropathic pain (Dunlop et al., 2009; Lewis et al., 2011) [7, 8].
  • Non-selective HCN blockers have been shown to attenuate pain symptoms in rodent neuropathic pain models (Descoeur et al., 2011; Young et al., 2014) [9, 10].
  • Their cardiac and visual side effects e.g. pan-HCN blockers
  • pan-HCN blockers however limit the clinical translation of their use to treat neuropathic pain.
  • HCN channels are tightly regulated by an auxiliary subunit, the Rab8b interacting protein (TRIP8b) which is not expressed in the heart.
  • TRIP8b the Rab8b interacting protein
  • This cytoplasmic protein binds to the C-terminus of HCN channel subunits via two contact sites (Lewis et al., 2009)
  • TPR tetratricopeptide region
  • the present invention is based on the hypothesis that the disruption of TRIP8b-HCN interactions leading to a decrease in currents (Ih) induced by HCN channels, could have an analgesic effect in models of acute and chronic peripheral neuropathies induced by oxaliplatin. in rodents faithfully reproducing human symptoms.
  • NUCC-5953 a molecule resulting from a screening of a library of 20,000 molecules, capable of disrupting the TRIP8b-HCN interaction (Han et al., 2015) [13].
  • the inventors have thus demonstrated that the acute hypersensitivity to cold induced by oxaliplatin is reversed in a dose-dependent manner by intrathecal (Figure 2) or systemic ( Figure 3) injection of NUCC-5953. No alteration in locomotor activity was observed.
  • Preliminary data also showed that administration of NUCC-5953 reduces membrane addressing, and therefore HCN1 and 2 activity observed in neuropathic animals (Figure 5B).
  • in vitro application of NUCC-5953 showed no effect on currents induced by HCN activation in cardiac cells (unlike non-specific HCN channel blockers, Figure 6).
  • the inventors then decided to design specific blockers of the TRIP8b-HCN interaction based on the mode of interaction of the two proteins.
  • PPI protein-protein interactions
  • Low molecular weight molecules although widely screened, are poorly suited to compete with interactions involving large surface areas (>800 ⁇ ).
  • Peptides are the compounds of choice for designing these new inhibitors provided that they can solve the problems of metabolic and conformational stability, but also of cell penetration to reach intracellular targets.
  • peptoids N-substituted glycine oligomers
  • peptomers /.e . oligomers combining "peptoide” monomers and "amino-acid” monomers - Ostergaard et al 1997 [17] - or peptide-peptoide hybrids).
  • the inventors have therefore designed new peptoids targeting the interaction between the TPR domains of TRIP8b and the C-terminal end of HCN, capable of exerting an analgesic effect in a model of acute neuropathy induced by oxaliplatin without cardiac or unwanted visuals.
  • R 1 is independently CH 3 (L-Ala), CH(CH 3 ) 2 (L-Val), CH(CH 3 )CH 2 CH 3 (L-lle), CH 2 CH(CH 3 ) 2 ( L-Leu and D-Leu), CH 2 C(CH 3 ) 3 , C(CH 3 ) 3 , CH 2 (cyclobutyl);
  • R 2 , R 3 , and R 4 are the side chains of the peptoid units incorporated sequentially during the synthesis from primary amines;
  • R 2 and R 3 are chosen independently from: CH 2 CH(CH 3 ) 2 , CH 2 CH 2 NH 2 , CH 2 CH 2 OH, CH 2 CH 2 CH 2 OH, CH 2 CH(OH)CH 3J CH 2 CONH 2J CH 2 CH 2 CONH 2 .
  • the side chains having an alcohol or amine function have been incorporated into the oligomers in protected form: silyl ether for the alcohol function and tert-butyl carbamate (Boc) for the amine function;
  • R 4 is an aliphatic or aromatic group chosen from:
  • R 5 is independently CH3, CH(CHs)2, CH2C6H5, CeF X (where X in ortho, meta or para position is independently H, OMe, CF3, CH3, CH2CH3, F, Br,
  • R 4 is an aliphatic or aromatic group chosen from:
  • R 5 is independently CH3, CH2C6H5, CeF X (where X in the ortho, meta or para position is independently H, OMe, CF3, CH3, CH2CH3, F, Br, Cl), 3-indolyl, 3 -quinolinyl.
  • the peptoids of the present invention are chosen from the peptoids of general formula (I) in which:
  • R 1 is independently CH3 (L-Ala), CH(CHs)2 (L-Val), CH(CH 3 )CH 2 CH 3 (L-lle), CH 2 CH(CH 3 )2 (L -Leu and D-Leu), CH 2 C(CH 3 )3, C(CH 3 ) 3 , CH 2 (cyclobutyl);
  • R 2 , R 3 , and R 4 are the side chains of the peptoid units incorporated sequentially during the synthesis from primary amines;
  • R 2 and R 3 are chosen independently from: CH2CH2NH2, CH2CH2OH, CH2CH2CH2OH, CH 2 CH(OH)CH 3 , CH2CONH2, CH2CH2CONH2.
  • the side chains having an alcohol or amine function have been incorporated into the oligomers in protected form: silyl ether for the alcohol function and tert-butyl carbamate (Boc) for the amine function;
  • R 4 is an aliphatic or aromatic group chosen from:
  • R 5 is independently CH3, CH2C6H5, C6H4X (where X in ortho, meta or para position is independently H, OMe, CF3, CH3, CH2CH3, F, Br,
  • the peptoids of the present invention contain 2 carbon atoms on the second unit (starting from the C-terminal end).
  • the peptoids of the present invention are chosen from the peptoids of general formula (I′) below: or
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined above.
  • the peptoids of the present invention have the following formulas:
  • a subject of the present invention is also an intermediate for the synthesis of the peptoid of general formula (I), the said peptoid comprising 3 units.
  • Said synthetic intermediate is a peptoid of general formula (II) below: or
  • R 1 , R 2 and R 3 are as defined above;
  • R 6 is H, R 3 , COR 5 (where R 5 is as defined above) or R 7 ;
  • R 7 is independently one of:
  • a subject of the present invention is the peptoids of formula (II) in which R 6 is H.
  • a subject of the present invention is the peptoids of formula (II) in which R 6 is COR 5 .
  • a subject of the present invention is the peptoids of formula (II) in which R 6 is R 7 .
  • a subject of the present invention is the peptoids of formula (II) in which R 6 is R 3 .
  • the peptoids according to the invention can be chosen from the following peptoids of general formulas (Ha), (IIb), (Ile) and (I Id):
  • WHERE R 1 , R 2 , R 3 , R 5 and R 7 are as defined above.
  • the peptoids of the present invention contain 2 carbon atoms on the second unit (starting from the C- end terminal).
  • the peptoids are chosen from the following peptoids of formulas (IT), (I l'a), (H'b), (H'c) or (H'd):
  • R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as defined above.
  • a subject of the present invention is also a pharmaceutical composition comprising a peptoid according to the present invention, and a pharmaceutically acceptable vehicle.
  • the present invention also relates to a peptoid or a pharmaceutical composition according to the present invention for use as a medicament.
  • the present invention also relates to a peptoid or a pharmaceutical composition according to the invention for use in the prevention or treatment of chronic pain, in particular chronic pain of neuropathic origin, more particularly peripheral neuropathic pain by example induced by chemotherapy.
  • the peptoids of the present invention can have a significant impact on improving the quality of life of patients suffering from neuropathic pain induced by anti-cancer drugs and possibly their survival.
  • the HCN channels are also involved in the etiology of various pains of neuropathic and inflammatory origin, the peptoids of the present invention open the way to new classes of analgesic drugs active more broadly on different types of chronic pain.
  • Figure 4 represents the histograms showing the latency to the fall (A) and to the speed of the fall (B) of mice treated with the vehicle or NUCC5953 (4 mg/kg, sc) subjected to a rotarod test at increasing speed ( from 4 to 40 rpm for 10 min).
  • Figure 5 depicts (A) study design (B) subcellular (membrane) expression of HCN1, HCN2 and TRIP8b in DRGs from animals treated with vehicle (V), oxaliplatin (O) or l oxaliplatin+NUCC5953 (5 nmol, i.t.) (N).
  • V vehicle
  • O oxaliplatin
  • N l oxaliplatin+NUCC5953
  • Figure 6 represents the absence of effect of NUCC5953 on the amplitude of the If current unlike ivabradine (IVA).
  • Figure 8 represents the molecular dynamics of TRIP8b in interaction with the SNL peptide.
  • Figure 11 shows bar graphs showing fall latency (A) and fall velocity (B) of mice treated with vehicle, YC55 (2.5, 5 or 10 mg/kg, s.c.) or valium ( 2.5 mg/kg, s.c.) subjected to a rotarod test at increasing speed (from 4 to 40 rpm for 10 min).
  • mice were carried out on male C57BI/6JR] mice weighing 20 to 24 g or male Sprague-Dawley rats weighing 150 to 175 g supplied by the Janvier laboratories (France), maintained at a light/dark cycle of 12 hours and fed and watered ad libitum. Behavioral experiments were performed blind, in a quiet room, by the same experimenter for a given test with great care taken to minimize or avoid animal discomfort. All animal procedures were approved by the local animal ethics committee and the experiments were performed according to the guidelines provided by the European Community regarding the care and use of animals (Directive 2010/63/EU).
  • Von Frey test The mechanical sensitivity was evaluated with calibrated Von Frey filaments of 0.07 g, 0.6 g or 1.4 g. The filaments were applied five times in order of increasing stiffness, perpendicular to the plantar surface of the hind paw and pressed until they bent. The number of responses for a given filament strength was counted.
  • Paw pressure test in rats Rats were subjected to the paw pressure test previously described by Randall and Selitto (1957) [15]. Nociceptive thresholds, expressed in grams, were measured with a Ugo Basile analgesimeter (Apelex, probe tip diameter 1 mm, weight 30 g) by applying increasing pressure to the rats right hind paw until the obtaining a sign of pain (vocalization threshold) (the cut-off was 750 g). Before the treatments, the rats were accustomed to the test by handling them without subjecting them to paw pressure. Then, after obtaining two consecutive stable vocalization threshold values, the treatment effects were evaluated after 15, 30, 45, 60, 90 and 120 min. The results are expressed in the form of vocalization thresholds, in grams.
  • the areas under the time course curves (AUC, g. min) of the antihyperalgesic effects were calculated from the individual scores at each time, using the trapezoidal method. Data were analyzed by a two-way ANOVA followed by a Bonferroni test, when the time course of effects was investigated. A one-way ANOVA followed by a Student Newman-Keuls test was used to analyze the effect of the different treatments determined by the ASCs. The level of statistical significance was set at p ⁇ 0.05.
  • Rotarod test For the Rotarod test (Bioseb), the animals were first accustomed to remaining on the stationary cylinder for 10 min before moving on to another 10 min with a rotation speed of 4 revolutions per minute. The animals received the drug immediately after training and the test was performed 30 minutes later. The test consisted of measuring the fall latency of the animals when the rotation passes from 4 to 40 rpm linearly over 5 min. The mean of the two closest values over 3 trials was calculated.
  • Oxaliplatin-Induced Acute Neuropathy in Mice Mice received an intraperitoneal (ip) injection of oxaliplatin at 6 mg/kg dissolved in glucose at 5% directly after the first behavioral evaluation. 90 hours after drug administration, corresponding to the time required to reach the peak of hyperalgesia (Descoeur et al., 2011) [9], a second evaluation of cold sensitivity and mechanical sensitivity was performed.
  • Acute paclitaxel-induced neuropathy in rats Rats were injected i.p. dimethyl sulfoxide (DMSO; solvent) or 1 mg/kg/1 mL of paclitaxel (Sigma-Aldrich, Lyon, France) on days D0, D2, D4 and D7. The behavior test was carried out on the day of the first injection of paclitaxel (D0) and on days 10 (D10) and 14 (D14) after the injection of paclitaxel.
  • DMSO dimethyl sulfoxide
  • RNA isolation and quantification DRG pairs from the L4 to L6 lumbar segments were dissected and pooled. RNA was extracted using TRIzol® reagent (Nitrogen) according to the manufacturer's instructions (Thermofisher). The quality of the RNA was evaluated by the Agilent 2100 bioanalyzer (Agilent Technologies), the samples whose RIN (RNA Integrity Number) was greater than 8 were kept for subsequent analyses. Reverse transcription was performed with Superscript II reverse transcriptase according to the protocol provided by Invitrogen.
  • the amplification was carried out using the Light Cycler Fast Start DNA kit (Roche diagnostic) and the quantity of real-time DNA was measured with a Mastercycler Realplex thermal cycler (Eppendorf). The average of the relative amount of cDNA from each triplicate was calculated using a standard concentration curve and normalized to the GUS gene cDNA.
  • the amplification conditions were as follows: preincubation for 7 min at 95°C followed by 50 cycles of 20 s at 95°C and 20 s at the specific hybridization temperature of the pair of primers followed by 20 s at 72 °C.
  • RNA sequencing We used RNA sequencing analysis on DRG L4-L5-L6 from mice treated with oxaliplatin (3mg/kg, i.p.) or vehicle twice weekly for 3 weeks . At the end of the experiment (D21), the mice were anesthetized and killed, and the L4-L5-L6 DRGs were quickly harvested, frozen in liquid nitrogen, and stored at -80°C until to their use. Total RNAs from DRGs L4-L5-L6 were extracted using the RNeasy Micro kit (Qiagen) according to the manufacturer's protocol and Ribosomal RNA removed using Ribo-Zero Plus rRNA depletion kit (Illumina).
  • RNA concentration was determined using the Take3 nucleic acid quantification plate (Epoch, BioTek, USA). RNA integrity was analyzed by a capillary electrophoresis instrument (Fragment Analyser, Agilent®) and sent to Fasteris (https://www.fasteris.com) for RNA sequencing. Libraries were prepared using the TruSeq protocol from Illumina and SBS-based sequencing was performed using a HiSeq 2500 platform (Illumina).
  • the analysis was carried out in different steps: splice junction mapping (TopHat2), counting (HTSeq-count), filtering, normalization (edgeR, DESeq and DESeq2) and differential analysis (edgeR, DESeq and DESeq2) carried out by Benjamin Bertin and Yoan Renaud (GreD, Clermont-Ferrand).
  • Membrane fractionation Tissues were homogenized in HEPES buffer (20mM HEPES pH 7.4, 320mM sucrose, 5mM EDTA, 5mM EGTA) containing protease inhibitors at 4°C, sonicated and centrifuged at 1000 g for 15min at 4°C. The pellets were removed. For organelle spin, supernatants were centrifuged at 15,000g for 10 min at 4°C and organelle pellets were retained. For cytosolic spin, supernatants were centrifuged at 100,000g for 1 hour at 4°C. The cytosolic fraction was in the supernatants and the membrane fraction in the pellets.
  • the membrane pellets were then resuspended in SB buffer (20mM HEPES pH 7.4, 1 M Kl, 5mM EDTA, 5mM EGTA at 4 degrees) and centrifuged at 100,000 g for 1 hour at 4°C to eliminate weakly bound membrane proteins.
  • the membrane fractions were then resuspended in RB buffer (20mM HEPES pH 7.4, 100mM NaCl, 5mM EDTA, 5mM EGTA) containing Triton (1%) and protease inhibitors. After sonication in an ice bath, the fractions membranes were then subjected to gentle agitation for 2 hours at 4°C. °C. The solubilized membrane fractions were centrifuged at 100,000 g for 1 hour at 4°C. The membrane fraction was in the supernatant.
  • the corresponding HRP-coupled secondary antibodies (ThermoFisher) were incubated at a 1/10,000 dilution and detected with the chemiluminescent substrate (SuperSignal West Pico Chemiluminescent Substrate, Thermofisher).
  • Fluorescence polarization assay A fluorescence polarization (FP) based assay was used to identify compounds capable of disrupting the interaction between HCN and the TRIP8b tail, as published (Han et al., 2015) [13], EXAMPLE 2: RESULTS
  • TRIP8b mRNA RNAseq data obtained from DRG mice show the presence (FPKM>1) of splice variants 2 to 5: NM_01163516, NM_01163517, NM_01289505, NM_01310460
  • the expression of HCN1-2 channel and TRIP8b transcripts and proteins was significantly increased in peripheral neurons of oxaliplatin-treated animals compared to controls, suggesting the involvement of the 2 proteins in the development of OIPN (mouse model of oxaliplatin-induced neuropathy) ( Figure 1A-C).
  • NUCC5953 did not affect heart rate in vivo when administered at an analgesic dose (4mg/kg, i.p.) (Figure 7). The results show that the average heart rate is not modified in three mice before (A), at the time of injection of NUCC5953 (B) and 30 minutes after injection (C).
  • Peptoid compounds mimicking the sequence of the carboxy-terminus of the HCN2 channel have been designed and synthesized.
  • the design of these peptidomimetics was based on an in-depth study of the X-ray structure of a co-crystal of TRIP8b with the C-terminal region of HCN2, available in the protein database (pdb: 4EQF).
  • Preparatory modeling work intended to complete and improve this structure has been carried out.
  • the missing parts were modeled by sequence homology from different PEX5 structures (PDB: 1 FCH, 3R9A, 4KXK, 4KYO, 2J9Q, 2C0M and 2C0L) showing a sequence identity ranging from 30 to 60% with TRIP8b.
  • the resulting model made it possible to identify the contacts between residues responsible for the formation of the HCN-TRIP8b complex.
  • This study notably made it possible to identify two hydrophobic pockets of the TPR domain of TRIP8b, essential for a good affinity of the ligands to this protein domain (FIG. 8).
  • Hydrophobic pocket 1 of TRIP8b anchors the side chain of the C-terminal residue of the ligands. Efficient interaction of the ligands with the hydrophobic pocket 2, located near the central region of TRIP8b, identified as a binding site to the CNBD domain of HCN, also makes it possible to reinforce the affinity of the inhibitors.
  • Several peptide-peptoid hybrid oligomers of 4 residues and bearing various side chains capable of targeting these hydrophobic pockets have been designed and evaluated by molecular dynamics (MD).
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined previously.
  • the compounds are hybrid peptide-peptoid oligomers (peptomers) (Ostergaard et al., 1997) [17], They comprise four residues including an ⁇ -amino acid positioned at the C-terminal end of the sequence, and three peptoid residues consecutive. The third residue (from the N-terminus) is either an R>-peptoid unit or an a-peptoid unit.
  • ⁇ -peptoids generally called “peptoids” refer to N-substituted glycine oligomers (Simon et al., 1992) [18].
  • R>-peptoids are oligomers composed of N-substituted R>-aminopropionic acid units (Hamper et al., 1998) [19].
  • an R>-peptoid residue contains an additional methylene group in the backbone compared to an ⁇ -peptoid residue.
  • Peptoids exhibit advantageous characteristics for the development of bioactive compounds. They lend themselves to solid-phase synthesis, using an iterative so-called "submonomer” approach in which each new unit is constructed in two steps (Zuckermann et al., 1992) [20].
  • Peptoids can incorporate a wide variety of side chains, both proteinogenic side chains and unnatural side chains (Culf et al., 2010) [21], “Submonomer” syntheses use simple starting molecules such as l bromoacetic acid and primary amines for the construction of ⁇ -units and acryloyl chloride and primary amines for the construction of R>-peptoid units.
  • the primary amines, from which the side chains are incorporated, are commercially available in the hundreds, or can be prepared before use if desired.
  • the peptoid skeleton based on N, /V-disubstituted amides has been shown to be resistant to proteases (Miller et al., 1995) [22], The presence of tertiary amide bonds also gives them better permeability (Kwon et al., 2007; Vollrath et al., 2013) [23, 24], and some studies tend to show that peptoids are less immunogenic than peptides (Li et al., 2010; Chongsiriwatana et al., 2008) [25, 26].
  • the crude peptomer compounds were analyzed by LC-MS and then purified on C18 flash chromatography cartridges with UV detection at 214 and 220 nm. Pure fractions were pooled and lyophilized. The pure compounds were analyzed by reverse phase HPLC on a Nucleodur® C4 column (5 ⁇ m, 300 A, 250 mm ⁇ 4.6 mm). Table 2 below presents the HRMS and HPLC data of the compounds. Table 2 at LCMS.
  • R 1 is independently CH 3 (L-Ala), CH(CH 3 ) 2 (L-Val), CH(CH 3 )CH 2 CH 3 (L-lle), CH 2 CH(CH 3 ) 2 ( L-Leu and D-Leu), CH 2 C(CH 3 ) 3 , C(CH 3 ) 3 , CH 2 (cyclobutyl);
  • R 2 , R 3 , and R 4 are the side chains of the peptoid units incorporated sequentially during the synthesis from primary amines;
  • R 2 and R 3 are chosen independently from: CH2CH(CH 3 )2, CH2CH2NH2, CH2CH2OH, CH2CH2CH2OH, CH 2 CH(OH)CH 3 , CH2CONH2, CH2CH2CONH2.
  • the side chains having an alcohol or amine function have been incorporated into the oligomers in protected form: silyl ether for the alcohol function and tert-butyl carbamate (Boc) for the amine function;
  • R 4 is an aliphatic or aromatic group chosen from:
  • R 5 is independently CH3, CH(CHs)2, CH2C6H5, CeF X (where X in ortho, meta or para position is independently H, OMe, CF3, CH3, CH2CH3, F, Br,
  • DIEA diisopropylethylamine
  • Fmoc fluorenylmethyloxycarbonyl
  • DMF N,N-dimethylformamide
  • DIC diisopropylcarbodiimide
  • HFIP 1,1,1,3,3,3-hexafluoroisopropanol
  • ta ambient temperature
  • TFA trifluoroacetic acid
  • 2-chlorotrityl chloride resin (1.33 mmol g -1 , 0.100 g, 0.133 mmol) was swollen in 2 mL of dry CH2Cl2 (2 x 20 min). After filtration, 0.12 mL of a 2.2 M solution of Fmoc-Leu-OH in CH2Cl2 (2.0 equivalents) was added, followed by 2.0 mL of a 0.4 M solution of DIEA in CH2Cl2 (6.0 equivalents). The mixture was stirred for 40 min at 25°C.
  • the resin was drained, washed with CH2Cl2 (2 x 2 mL) and the attachment of Fmoc-Leucine to the resin was repeated under the same conditions.
  • the resin was washed with CH2Cl2 (5 x 2 mL).
  • the Fmoc group was removed by adding 2.0 mL of a 20% solution of piperidine in DMF and stirring for 15 minutes at room temperature. The operation was repeated under the same conditions, after which the resin was washed with DMF (5 x 2 mL) and drained.
  • the resin was cooled by two washes with CH2Cl2 at -20°C. 1.21 mL of a 0.22 M solution of acryloyl chloride (2.0 equivalents) in CH2Cl2 cooled to -20°C was added, followed by 0.8 mL of a 0.5 M solution of EtsN (3.0 equivalents) in chilled CH2Cl2 (-20°C). The resin was stirred for 1 hour at 25°C, drained, then treated again with acryloyl chloride under the same conditions. The resin was filtered and washed with CH2Cl2 (5 x 2 mL), then drained.
  • the acrylamide obtained was treated with a 2.0 M solution of the amine R 2 NH2 in isopropanol (12.0 equivalents) for 24 h at 50°C. After filtration of the resin, the aza-Michael reaction was repeated under the same conditions. The resin was washed with isopropanol (5 x 2 mL) before submonomer synthesis of two ⁇ -peptoid residues.
  • the resin was treated with 1.5 mL of a 2.4 M solution of HFIP in CH2Cl2. After stirring for 40 minutes at 25°C, the resin was filtered and washed with CH2Cl2 (5 x 2 mL). The solvent was removed under reduced pressure. Finally, the silylated or Boc protecting groups of the side chains were removed by treatment of the peptomer with 2 mL of 25% (v/v) TFA in CH2Cl2 for 10 minutes at room temperature. The reaction mixture containing the final product was diluted with CH2Cl2 (5 mL) before complete evaporation under vacuum. In order to eliminate all traces of TFA, the product dissolved in CH2Cl2 was evaporated under vacuum, repeating this operation 5 times.
  • Benzoylation To the resin was added 0.8 mL of a 1.0 M solution of benzoyl chloride in CH2Cl2 (6.0 equiv.), followed by 0.8 mL of a 2.0 M solution of DIEA in CH2Cl2 (12.0 equiv.). After stirring for 40 minutes at 25°C, the resin was drained and washed with CH2Cl2 (5 x 2 mL).
  • lead compound YC55 demonstrated a dose-dependent analgesic effect in OIPN mice when administered i.t. ( Figure 9).
  • Compound YC55 also demonstrated a dose-dependent analgesic effect in OIPN mice when administered s.c. ( Figure 10).
  • YC55 also demonstrated a dose-dependent analgesic effect in a rat model of paclitaxel-induced neuropathy when administered i.t. ( Figure 12).
  • Intrathecal administration of YC55 showed an antihyperalgic effect in a model of neuropathy induced by traumatic sciatic nerve injury (Figure 13), suggesting that the strategy of disrupting the TRIP8b interaction may have an analgesic effect in several states. of neuropathic pain.
  • Trimeric peptomeric compounds are also mimics of the sequence of the carboxy-terminal end of the HCN2 channel. They were designed in based on the in-depth study of the X-ray structure of a co-crystal of
  • ligands have a formula which is represented by the formula LF369 below or the following general formula (II): or
  • R 1 , R 2 and R 3 are as defined above;
  • R 6 is H, R 3 , COR 5 (where R 5 is as defined above), or R 7 ;
  • R 7 is independently one of:
  • the compounds are hybrid peptide-peptoid oligomers (peptomers) (Ostergaard et al., 1997) [17], They comprise three units including an ⁇ -amino acid positioned at the C-terminal end of the sequence, followed by two residues peptoid.
  • the syntheses were carried out in solution starting from an ⁇ -amino acid protected in the form of a tert-butyl ester (Xaa-fBu, L-Leu-fBu in the case of the synthesis of LF369). These syntheses can also be carried out on resin as previously described for the tetrameric peptidomimetics. From this unit, the elongation was carried out as for the molecules corresponding to the general formula (I), by approaches of "sub-monomer chemistry".
  • the central unit is of the p-peptoid type
  • the two steps necessary for its construction are the reaction of Xaa-fBu with acryloyl chloride, followed by an aza-Michael reaction allowing the introduction of the desired side chain (R 2 ) to the backbone
  • the third a-peptoid unit is constructed by acylation of the dimer with bromoacetic acid bromide followed by substitution of the bromine atom by an amine.
  • R 6 is H
  • the amine used is a primary amine R 3 NH2.
  • the secondary amine obtained after treatment with R 3 NH2 is acylated by a chloride acid, an acid anhydride or a carboxylic acid under coupling conditions.
  • the final step is to deprotect the side chains and the C-terminus by treatment with TFA.
  • the salts formed are removed by filtration, the filtrate is evaporated under vacuum and the product obtained is purified by chromatography on silica gel (50/50 cyclohexane/AcOEt).
  • the acrylamide is isolated with a yield of 93% (1.76 g, 7.27 mmol) in the form of a white solid.
  • Dimer acylation reaction The dimer (2.74 g, 6.58 mmol) is dissolved in 10 mL of THF, the reactor is inerted with argon then cooled to -20°C. Triethylamine (1.1 mL, 7.89 mmol, 1.2 equiv.) is added to the solution, followed by the addition of 2-bromoacetyl bromide (0.62 mL, 7.89 mmol, 1. 2 equiv.). After 3 hours of stirring at -20°C, the reaction mixture is filtered. The filtrate obtained is evaporated and the reaction crude is chromatographed on silica gel (60/40/0.1 Cyclohexane/AcOEt/EtsN). The bromoacetylated dimer is isolated pure with a yield of 67% (2.36 g, 4.4 mmol) as a yellowish oil.
  • the crude product is purified by chromatography on silica gel (95/5/0.1 AcOEt/MeOH/EtsN) leading to the trimer with a yield of 83% (2.30 g, 3.64 mmol) in the form of an oil.
  • the crude product obtained is chromatographed on silica gel (90/10/0.1 AcOEt/cyclohexane/EtsN) leading to the N-acetylated trimer with a yield of 92% (2.27 g, 3.36 mmol) in the form colorless oil.
  • the trimeric compound (502 mg, 0.776 mmol, 1 equiv.) is dissolved in 4 mL of a TFA/CH2Cl2/H2O mixture (47.5:47.5:5). After 2 hours of stirring at room temperature, 10 mL of dichloromethane are added. The reaction medium is evaporated under vacuum then 5 co-evaporations with dichloromethane are carried out. The product is then redissolved in 5 mL of distilled water and then left under stirring at room temperature for 2 h. The solvent is evaporated then five co-evaporations with toluene are carried out leading to LF369 (362 mg) in the form of an oil.
  • R 1 , R 2 and R 3 are as defined above;
  • R 6 is R 3 , H, COR 5 (where R 5 is as defined previously), or R 7 ;
  • R 7 is independently one of:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/FR2021/051694 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique Ceased WO2022074313A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA3194875A CA3194875A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
JP2023521558A JP7853288B2 (ja) 2020-10-06 2021-09-30 新規ペプトイド及び慢性疼痛の予防又は治療におけるそれらの使用
CN202180068718.2A CN116744957A (zh) 2020-10-06 2021-09-30 新类肽及其在预防或治疗慢性疼痛中的用途
ES21798748T ES3005857T3 (en) 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain
EP21798748.6A EP4225295B1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
US18/248,240 US20230374067A1 (en) 2020-10-06 2021-09-30 Novel peptoids and use thereof for preventing or treating chronic pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRFR2010186 2020-10-06
FR2010186A FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Publications (1)

Publication Number Publication Date
WO2022074313A1 true WO2022074313A1 (fr) 2022-04-14

Family

ID=74553909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2021/051694 Ceased WO2022074313A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Country Status (8)

Country Link
US (1) US20230374067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225295B1 (cg-RX-API-DMAC7.html)
JP (1) JP7853288B2 (cg-RX-API-DMAC7.html)
CN (1) CN116744957A (cg-RX-API-DMAC7.html)
CA (1) CA3194875A1 (cg-RX-API-DMAC7.html)
ES (1) ES3005857T3 (cg-RX-API-DMAC7.html)
FR (1) FR3114739B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022074313A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
KR20080038408A (ko) * 2005-08-18 2008-05-06 쉬바르츠파르마에이지 근육통 치료를 위한 펩티드 화합물의 신규한 용도
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP7120927B2 (ja) * 2016-06-07 2022-08-17 江蘇恒瑞医薬股▲ふん▼有限公司 フェニルプロパンアミド誘導体ならびにそれらの製造方法および医薬用途
US11753432B2 (en) * 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
BANKSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 109, 2012, pages 7899
CHONGSIRIWATANA ET AL., PROC. NATL. ACAD SCI. USA, vol. 105, 2008, pages 2794 - 2799
CULF ET AL., MOLECULES, vol. 15, 2010, pages 5282 - 5335
DESCOEUR ET AL., EMBO MOL. MED., vol. 3, no. 5, 2011, pages 266 - 278
DUNLOP ET AL., CURR. PHARM. DES., vol. 15, no. 15, 2009, pages 1767 - 1772
FINNERUP ET AL., LANCET NEUROL., vol. 14, no. 2, 2015, pages 162 - 173
HAMPER ET AL., J. ORG. CHEM., vol. 63, 1998, pages 708 - 718
HAN ET AL., J. BIOMOL. SCREEN, vol. 20, no. 9, 2015, pages 1 - 8
HERSHMAN ET AL., J. CLIN. ONCOL., vol. 32, no. 18, 2014, pages 1941 - 1967
HRUBY VICTOR J ED - MERCER JULIAN: "Multivalent peptide and peptidomimetic ligands for the treatment of pain without toxicities and addiction", PEPTIDES, vol. 116, 2019, pages 63 - 67, XP085693658, ISSN: 0196-9781, DOI: 10.1016/J.PEPTIDES.2019.02.004 *
JANSSEN ET AL., ARZNEIMITTELFORSCHUNG, vol. 13, 1963, pages 502 - 507
KIMCHUNG, PAIN, vol. 50, no. 3, 1992, pages 355 - 363
KWON ET AL., J. AM. CHEM. SOC., vol. 129, 2007, pages 1508 - 1509
LEWIS ET AL., J. NEUROSCI., vol. 29, no. 19, 2009, pages 6250 - 6265
LEWIS ET AL., MOL. CELL NEUROSCI., vol. 46, no. 2, 2011, pages 357 - 367
LI ET AL., CELLULAR & MOLECULAR IMMUNOL., vol. 7, 2010, pages 133 - 142
LUDWIG ET AL., NATURE, vol. 393, no. 6685, 1998, pages 587 - 591
MARGER ET AL., CHANNELS (AUSTIN, vol. 5, no. 3, 2011, pages 241 - 250
MESIRCA ET AL., NAT. COMMUN., vol. 5, 2014, pages 4664
MILLER ET AL., DRUG DEV. RES., vol. 35, 1995, pages 20 - 32
OSTERGAARD ET AL., MOLECULAR DIVERSITY, vol. 3, 1997, pages 17 - 27
RANDALLSELITTO, ARCH. INT. PHARMACODYN. THER., vol. 111, no. 4, 1957, pages 409 - 419
SANTORO ET AL., CELL, vol. 93, no. 5, 1998, pages 717 - 729
SEIFERT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, no. 16, 1999, pages 9391 - 9396
SIMON ET AL., PROC. NATL. ACAD. SCI USA, vol. 89, 1992, pages 9367 - 9371
VOLLRATH ET AL., ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 11, 2013, pages 8497 - 8201
VON HEHN ET AL., NEURON, vol. 73, no. 4, 2012, pages 638 - 652
YOUNG ET AL., PAIN, vol. 155, no. 9, 2014, pages 1708 - 1719
ZUCKERMANN ET AL., J. AM. CHEM. SOC., vol. 114, 1992, pages 10646 - 10647

Also Published As

Publication number Publication date
US20230374067A1 (en) 2023-11-23
EP4225295B1 (fr) 2024-11-13
JP7853288B2 (ja) 2026-04-28
EP4225295C0 (fr) 2024-11-13
CA3194875A1 (fr) 2022-04-14
CN116744957A (zh) 2023-09-12
EP4225295A1 (fr) 2023-08-16
ES3005857T3 (en) 2025-03-17
JP2023544842A (ja) 2023-10-25
FR3114739B1 (fr) 2022-08-26
FR3114739A1 (fr) 2022-04-08

Similar Documents

Publication Publication Date Title
JP7535549B2 (ja) 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのbcl-wポリペプチドおよび模倣物
Stromgaard et al. Recent advances in the medicinal chemistry of polyamine toxins
CN115209908A (zh) 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
EP2598523B1 (fr) Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
US20050090449A1 (en) Novel statine derivatives for the treatment of Alzheimer's disease
US11028128B2 (en) Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments
EP4225295B1 (fr) Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
CA2929286A1 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
EP4446335A1 (en) Novel peptide and use thereof
CA2565805A1 (fr) Conjugues tripeptidiques agonistes de la msh
US20140121168A1 (en) Antagonists of trpv1 receptor
US20090221513A1 (en) Treatment of Neurodegenerative Disorders
OA10403A (fr) Nouveaux peptides phényles leur procédé de préparation et les compositions pharmaceutiques qui en referment
FR2785613A1 (fr) Conotoxine isolee a partir du venin de conus ermineus, ses analogues et ses applications
García Myotoxin 3, a peptide from Crotalus oreganus rattlesnake venom as a microtubule-targeting agent
Wan Synthesis of β, γ-diamino acids and their use to design new analogues of the antimicrobial peptide Gramicidin Septide antimicrobien, la Gramicidine S
FR3092992A1 (fr) Inhibiteur d’acyl-thioestérases pour le traitement et/ou la prévention de la maladie de huntington
FR3061178A1 (fr) Peptides antimicrobiens et leurs utilisations
WO1992002544A1 (fr) Peptides de la famille des chromostatines
WO2003018618A2 (de) Katalyse der cis-trans isomerisierung von sekundären-amid peptidverbindungen
EP4702033A1 (en) Desmuramylpeptide diacids as nod2 agonists and use thereof
HK1191655A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21798748

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3194875

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2023521558

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202180068718.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021798748

Country of ref document: EP

Effective date: 20230508